Bcl-2 Inhibition or FBXW7 Mutation Sensitizes Solid Tumor Cells to HDAC Inhibition In Vitro but Could Prove Difficult to Validate in Patients
Pickering CR, Myers JN. Bcl-2 Inhibition or FBXW7 Mutation Sensitizes Solid Tumor Cells to HDAC Inhibition In Vitro but Could Prove Difficult to Validate in Patients. Cancer Discovery 2013, 3: 258-259. PMID: 23475877, DOI: 10.1158/2159-8290.cd-13-0019.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBiphenyl CompoundsCarcinoma, Squamous CellCell Cycle ProteinsF-Box ProteinsF-Box-WD Repeat-Containing Protein 7Histone Deacetylase InhibitorsHistone DeacetylasesHumansMyeloid Cell Leukemia Sequence 1 ProteinNitrophenolsPiperazinesProto-Oncogene Proteins c-bcl-2SulfonamidesUbiquitin-Protein Ligases